$2.8B Contract at Stake
PharmAthene Wins 50% of Profits; SIGA Plans Appeal
By Trista Morrison
Friday, September 23, 2011
PharmAthene Inc. scored a stunning victory in its five-year legal battle against SIGA Technologies Inc., with the Delaware Court of Chancery awarding PharmAthene half of the net profits from SIGA's smallpox drug ST-246, subject of a government contract worth up to $2.8 billion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.